Nordea Investment Management AB Has $55.49 Million Stock Position in Solventum Corporation $SOLV

Nordea Investment Management AB boosted its stake in shares of Solventum Corporation (NYSE:SOLV) by 6.1% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 732,860 shares of the company’s stock after purchasing an additional 41,991 shares during the period. Nordea Investment Management AB owned 0.42% of Solventum worth $55,492,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of SOLV. Independent Franchise Partners LLP boosted its position in Solventum by 263.1% during the first quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock valued at $442,608,000 after purchasing an additional 4,217,570 shares during the last quarter. Boston Partners boosted its position in Solventum by 101.3% during the first quarter. Boston Partners now owns 3,361,973 shares of the company’s stock valued at $255,554,000 after purchasing an additional 1,691,565 shares during the last quarter. Nuveen LLC acquired a new position in Solventum during the first quarter valued at approximately $35,375,000. Diamond Hill Capital Management Inc. boosted its position in Solventum by 139.6% during the first quarter. Diamond Hill Capital Management Inc. now owns 577,173 shares of the company’s stock valued at $43,888,000 after purchasing an additional 336,282 shares during the last quarter. Finally, Lord Abbett & CO. LLC acquired a new position in Solventum during the first quarter valued at approximately $23,572,000.

Solventum Trading Up 0.9%

Shares of SOLV stock opened at $72.11 on Friday. The firm has a 50 day moving average price of $72.63 and a two-hundred day moving average price of $71.95. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14. The company has a market capitalization of $12.50 billion, a PE ratio of 33.38, a price-to-earnings-growth ratio of 2.94 and a beta of 0.50. Solventum Corporation has a 12-month low of $60.70 and a 12-month high of $85.92.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.24. The firm had revenue of $2.16 billion during the quarter, compared to the consensus estimate of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period last year, the business posted $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. As a group, analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Wall Street Analysts Forecast Growth

SOLV has been the subject of several recent research reports. UBS Group started coverage on Solventum in a research report on Wednesday, October 1st. They set a “neutral” rating and a $77.00 price target for the company. Argus upgraded shares of Solventum from a “hold” rating to a “buy” rating and set a $90.00 target price for the company in a research note on Tuesday, July 1st. Weiss Ratings reiterated a “hold (c-)” rating on shares of Solventum in a research note on Wednesday, October 8th. Morgan Stanley upgraded shares of Solventum from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $80.00 to $103.00 in a research note on Tuesday, July 15th. Finally, Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a research note on Monday, September 15th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $84.89.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.